OC
REGN icon

Optimas Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Optimas Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,900
Closed -$3.2M – 40
2023
Q1 		$3.2M Buy
+3,900
New +$2.94M 2.69% 15

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Optimas Capital's REGN Position: Q2 2023 in Review

Optimas Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 3,900 shares — an estimated $3.2M sold.

Optimas Capital first reported a position in REGN in Q1 2023 and held it in 1 quarter. The position peaked at $3.2M in Q1 2023. 1,165 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

  • Optimas Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Optimas Capital sold 3,900 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $3.2M.
  • Optimas Capital first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Optimas Capital's Regeneron Pharmaceuticals position peaked at $3.2M in Q1 2023.
  • 1,165 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Optimas Capital's 13F filing for Q2 2023, filed 11 Aug 2023.